KaydedilenlerDerginizi ekleyin

Dergiler / Recent Trends in Pharmacology / 2025 / Volume: 3 Issue: 3

Orlistat-Induced Systemic Adverse Events: A Review of Case Reports And Public Health Implications

Murat Kösedağ(ATATÜRK ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ)0000-0003-0141-4689
Sayfa
—
Yayın Tarihi
2026-01-15
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, its unsupervised use and potential for abuse can lead to significant health risks, emphasizing the need for professional oversight.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Orlistat is a widely used gastrointestinal lipase inhibitor for obesity management.
📊
Temel Bulgular & Veri:This review aims to alert healthcare providers to the potential for significant adverse effects associated with Orlistat by synthesizing a collection of reported clinical cases.
💡
Sonuç & Katkı:However, its unsupervised use and potential for abuse can lead to significant health risks, emphasizing the need for professional oversight.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2025 Verileri
⚙️Değişkenler:Acute nephrotoxicity · acute pancreatitis · case reports

Abstract

Orlistat is a widely used gastrointestinal lipase inhibitor for obesity management. While its efficacy and safety are established under medical supervision, increasing unsupervised use has raised concerns regarding serious adverse events. This review aims to alert healthcare providers to the potential for significant adverse effects associated with Orlistat by synthesizing a collection of reported clinical cases. The review includes literature published between January 1988 and March 2025. We present case reports highlighting a range of adverse effects, including acute pancreatitis, hepatotoxicity, and acute oxalate nephropathy. These conditions are often linked to patient-specific vulnerabilities, pre-existing health conditions, or misuse, particularly among individuals with eating disorders. This review underscores the importance of careful patient selection, close monitoring, and increased awareness among family physicians, pharmacists, and other healthcare providers to ensure the safe use of Orlistat. When appropriately prescribed and monitored, Orlistat remains a valuable tool in obesity management. However, its unsupervised use and potential for abuse can lead to significant health risks, emphasizing the need for professional oversight.

🔖

Bu Makaleye Atıf Yap

Kösedağ, M. (2026). Orlistat-Induced Systemic Adverse Events: A Review of Case Reports And Public Health Implications. Recent Trends in Pharmacology, Volume: 3 Issue: 3. https://doi.org/10.62425/rtpharma.1770239

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (45)

  1. Abeer, Q., Abhilasha, J., Ornela, T., Haider, G., Moore, S., & Elona, S. (2025). Exploring Acute Pancreatitis After Orlistat Use: A Case Report. Cureus, 17(3).
  2. Ahmad, F. A., & Mahmud, S. (2010). Acute pancreatitis following orlistat therapy: report of two cases. JOP. Journal of the Pancreas, 11(1), 61-63.
  3. Ahmed, N., Nounou, M. I., Abouelfetouh, A., & El-Kamel, A. (2019). Over-the-counter herbal weight loss supplements in Egypt: label claim, microbiological and pharmaceutical quality, and safety assessments. Medical Principles and Practice, 28(2), 167-177.
  4. Algarni, M., Hadi, M. A., Yahyouche, A., Mahmood, S., & Jalal, Z. (2021). A mixed-methods systematic review of the prevalence, reasons, associated harms and risk-reduction interventions of over-the-counter (OTC) medicines misuse, abuse and dependence in adults. Journal of Pharmaceutical Policy and Practice, 14(1), 76. https://doi.org/10.1186/s40545-021-00350-7
  5. Bansal, A. B., Patel, P., & Al Khalili, Y. (2024). Orlistat. In StatPearls [Internet]. StatPearls Publishing.
  6. Buysschaert, B., Aydin, S., Morelle, J., Hermans, M. P., Jadoul, M., & Demoulin, N. (2016). Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease. Diabetes & Metabolism, 42(1), 62-64. https://doi.org/https://doi.org/10.1016/j.diabet.2015.08.006
  7. Chaudhuri, P. R., Santra, R., Palodhi, S., & Mondal, S. (2013). Orlistat‑induced acute pancreatitis in a type II diabetic and hypothyroid young woman: A case report. International Journal of Health & Allied Sciences, 2(4), 278.
  8. Daneschvar, H. L., Aronson, M. D., & Smetana, G. W. (2016). FDA-Approved Anti-Obesity Drugs in the United States. The American Journal of Medicine, 129(8), 879.e871-879.e876. https://doi.org/https://doi.org/10.1016/j.amjmed.2016.02.009
  9. Elsahoryi, N., Al-Sayyed, H., McGrattan, A., Odeh, M., & Hammad, F. (2021). Using of licensed and unlicensed anti-obesity medications among the university students. Nutrition and Food Processing.
  10. Fernández-Aranda, F., Amor, A., Jiménez-Murcia, S., Giménez-Martínez, L., Turón-Gil, V., & Vallejo-Ruiloba, J. (2001). Bulimia nervosa and misuse of orlistat: Two case reports. International Journal of Eating Disorders, 30(4), 458-461. https://doi.org/https://doi.org/10.1002/eat.1108
  11. Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008). Orlistat-associated adverse effects and drug interactions: a critical review. Drug safety, 31, 53-65.
  12. Flegal, K. M. (2023). Use and misuse of BMI categories. AMA Journal of Ethics, 25(7), 550-558. Guerciolini, R. (1997). Mode of action of orlistat. Int J Obes Relat Metab Disord, 21 Suppl 3, S12-23.
  13. Hadváry, P., Lengsfeld, H., & Wolfer, H. (1988). Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochemical Journal, 256(2), 357-361. https://doi.org/10.1042/bj2560357
  14. Hall, N. Y., Hetti Pathirannahalage, D. M., Mihalopoulos, C., Austin, S. B., & Le, L. (2024). Global Prevalence of Adolescent Use of Nonprescription Weight-Loss Products: A Systematic Review and Meta-Analysis. JAMA Network Open, 7(1), e2350940-e2350940. https://doi.org/10.1001/jamanetworkopen.2023.50940
  15. Handing, G., Pathak, U. I., Balasubramanian, A., Liu, A., & Mayer, W. A. (2022). Case - Orlistat-induced calcium oxalate crystalluria. Can Urol Assoc J, 16(10), 371-373. https://doi.org/10.5489/cuaj.7900
  16. Harp, J. B. (1998). An assessment of the efficacy and safety of orlistat for the long-term management of obesity. The Journal of Nutritional Biochemistry, 9(9), 516-521. https://doi.org/https://doi.org/10.1016/S0955-2863(98)00006-0
  17. Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000). Orlistat, a New Lipase Inhibitor for the Management of Obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 20(3), 270-279. https://doi.org/https://doi.org/10.1592/phco.20.4.270.34882
  18. Heymsfield, S. B., Segal, K. R., Hauptman, J., Lucas, C. P., Boldrin, M. N., Rissanen, A., Wilding, J. P. H., & Sjöström, L. (2000). Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Archives of Internal Medicine, 160(9), 1321-1326. https://doi.org/10.1001/archinte.160.9.1321
  19. Humayun, Y., Ball, K. C., Lewin, J. R., Lerant, A. A., & Fülöp, T. (2016). Acute oxalate nephropathy associated with orlistat. J Nephropathol, 5(2), 79-83. https://doi.org/10.15171/jnp.2016.14
  20. Hvizdos, K. M., & Markham, A. (1999). Orlistat. Drugs, 58(4), 743-760. https://doi.org/10.2165/00003495-199958040-00015
  21. Kose, M., Emet, S., Akpınar, T. S., Ilhan, M., Gok, A. F. K., Dadashov, M., & Tukek, T. (2015). An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis. Case Reports in Gastroenterology, 9(2), 152-155. https://doi.org/10.1159/000430433
  22. Lau, G., & Chan, C. L. (2002). Massive Hepatocellular Necrosis: Was it Caused by Orlistat? Medicine, Science and the Law, 42(4), 309-312. https://doi.org/10.1177/002580240204200405
  23. London, F., Thévenon, A., Levisse, C., Cassim, F., & Tard, C. (2018). Camptocormia and myalgia as the revealing symptoms of a drug-induced myopathy related to chronic orlistat intake: a case report. Acta Neurologica Belgica, 118(1), 115-118.
  24. Lucas, K. H., & Kaplan-Machlis, B. (2001). Orlistat—a novel weight loss therapy. Annals of Pharmacotherapy, 35(3), 314-328.
  25. MacWalter, R. S., Fraser, H. W., & Armstrong, K. M. (2003). Orlistat Enhances Warfarin Effect. Annals of Pharmacotherapy, 37(4), 510-512. https://doi.org/10.1345/aph.1C122
  26. Malhotra, S., & McElroy, S. L. (2002). Orlistat misuse in bulimia nervosa. American Journal of Psychiatry, 159(3), 492-a-493.
  27. McDuffie, J. R., Calis, K. A., Uwaifo, G. I., Sebring, N. G., Fallon, E. M., Hubbard, V. S., & Yanovski, J. A. (2002). Three‐month tolerability of orlistat in adolescents with obesity‐related comorbid conditions. Obesity Research, 10(7), 642-650.
  28. Mironica, A., Popescu, C. A., George, D., Tegzeșiu, A. M., & Gherman, C. D. (2024). Social Media Influence on Body Image and Cosmetic Surgery Considerations: A Systematic Review. Cureus, 16(7), e65626. https://doi.org/10.7759/cureus.65626
  29. Mittendorfer, B., Ostlund Jr, R. E., Patterson, B. W., & Klein, S. (2001). Orlistat Inhibits Dietary Cholesterol Absorption. Obesity Research, 9(10), 599-604. https://doi.org/https://doi.org/10.1038/oby.2001.79 Montero, J. L., Muntané, J., Fraga, E., Delgado, M., Costán, G., Serrano, M., Padillo, J., de la Mata, M., & Miño, G. (2001). Orlistat associated subacute hepatic failure. Journal of hepatology, 34(1), 173.
  30. Muls, E., Kolanowski, J., Scheen, A., Van Gaal, L., & Group, L. V. G. f. t. O. S. (2001). The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. International Journal of Obesity, 25(11), 1713-1721. https://doi.org/10.1038/sj.ijo.0801814
  31. Napier, S., & Thomas, M. (2006). 36 year old man presenting with pancreatitis and a history of recent commencement of orlistat case report. Nutrition journal, 5(1), 19. https://doi.org/10.1186/1475-2891-5-19
  32. Phan, D. T. A., Kongkaew, C., Heinrich, M., Dao, T. C. M., & Vo, T. H. (2025). From ‘traditional’remedies to ‘modern’supplements: a systematic review and meta-analysis of pharmaceutical adulteration in weight-loss natural products. Frontiers in Pharmacology, 16, 1594975.
  33. Ringman, J. M., & Mozaffar, T. (2008). Myopathy associated with chronic orlistat consumption: A case report. Neuromuscular Disorders, 18(5), 410-412. https://doi.org/https://doi.org/10.1016/j.nmd.2008.03.005
  34. Sall, D., Wang, J., Rashkin, M., Welch, M., Droege, C., & Schauer, D. (2014). Orlistat-induced fulminant hepatic failure. Clinical Obesity, 4(6), 342-347. https://doi.org/https://doi.org/10.1111/cob.12075
  35. SAYGILI, U. E. S., & ERDAL, M. (2001). Yeni Teknolojilerin Sağlik Sektöründeki Etkileri Ve Internet Kullanimi.
  36. Schwartz, S. M., Bansal, V. P., Hale, C., Rossi, M., & Engle, J. P. (2008). Compliance, Behavior Change, and Weight Loss With Orlistat in an Over-the-Counter Setting. Obesity, 16(3), 623-629. https://doi.org/https://doi.org/10.1038/oby.2007.96
  37. Singh, A. (2007). Acute oxalate nephropathy (first report) in a patient with chronic kidney disease: case report. Reactions, 1135, 20.
  38. Stalder, H., Oesterhelt, G., & Borgström, B. (1992). Tetrahydrolipstatin: Degradation products produced by human carboxyl-ester lipase. Helvetica Chimica Acta, 75(5), 1593-1603. https://doi.org/https://doi.org/10.1002/hlca.19920750513
  39. Steffen, K. J., Mitchell, J. E., le Grange, D., Crow, S. J., Attia, E., Bulik, C. M., Dellava, J. E., Bermudez, O., Erickson, A. L., Crosby, R. D., & Bansal-Dev, V. P. (2010). A prevalence study and Description of alli® use by patients with eating disorders. International Journal of Eating Disorders, 43(5), 472-479. https://doi.org/https://doi.org/10.1002/eat.20829
  40. Tushar, M. I., & Kersbergen, I. (2024). Factors associated with over-the-counter drug misuse among young people: a narrative review. European Journal of Public Health, 34(Supplement_3). https://doi.org/10.1093/eurpub/ckae144.1671
  41. Veeramachaneni, G. K., Raj, K. K., Chalasani, L. M., Annamraju, S. K., Js, B., & Talluri, V. R. (2015). Shape based virtual screening and molecular docking towards designing novel pancreatic lipase inhibitors. Bioinformation, 11(12), 535.
  42. Weir, M. A., Beyea, M. M., Gomes, T., Juurlink, D. N., Mamdani, M., Blake, P. G., Wald, R., & Garg, A. X. (2011). Orlistat and Acute Kidney Injury: An Analysis of 953 Patients. Archives of Internal Medicine, 171(7), 702-710. https://doi.org/10.1001/archinternmed.2011.103
  43. Wilson, N. S., Shah, N., Manitpisitkul, W., Twadell, W. S., Barth, R. N., Philosophe, B., & Fayek, S. A. (2011). Liver Failure Requiring Transplantation After Orlistat Use. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 31(11), 1145-1145. https://doi.org/https://doi.org/10.1592/phco.31.11.1145
  44. Zhang, X., Liu, J., Ni, Y., Yi, C., Fang, Y., Ning, Q., Shen, B., Zhang, K., Liu, Y., Yang, L., Li, K., Liu, Y., Huang, R., & Li, Z. (2024). Global Prevalence of Overweight and Obesity in Children and Adolescents: A Systematic Review and Meta-Analysis. JAMA Pediatr, 178(8), 800-813. https://doi.org/10.1001/jamapediatrics.2024.1576
  45. Zhu, J., Hu, M., Liang, Y., Zhong, M., Chen, Z., Wang, Z., Yang, Y., Luo, Z., Zeng, W., Li, J., Du, Y., Liu, Y., & Yang, C. (2024). Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database. Heliyon, 10(14). https://doi.org/10.1016/j.heliyon.2024.e34837